Following on from other more classic targeted therapies, such as EGFR inhibitors, it is likely that these medications will see increasing trial use in both the palliative and curative settings, though their ultimate impact on the state of NSCLC treatment is still uncertain. This evidence concerns the gene EGFR and non-small cell lung carcinoma.